Log in

NASDAQ:PTIProteostasis Therapeutics Stock Price, Forecast & News

$1.29
-0.04 (-3.01 %)
(As of 07/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.27
Now: $1.29
$1.36
50-Day Range
$1.29
MA: $1.43
$1.63
52-Week Range
$0.61
Now: $1.29
$4.72
Volume1.09 million shs
Average Volume1.28 million shs
Market Capitalization$67.27 million
P/E RatioN/A
Dividend YieldN/A
Beta1.21
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.
Read More
Proteostasis Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.10 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTI
CUSIPN/A
Phone617-225-0096

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5 million
Book Value$1.22 per share

Profitability

Net Income$-59,130,000.00

Miscellaneous

Employees44
Market Cap$67.27 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive PTI News and Ratings via Email

Sign-up to receive the latest news and ratings for PTI and its competitors with MarketBeat's FREE daily newsletter.

Proteostasis Therapeutics (NASDAQ:PTI) Frequently Asked Questions

How has Proteostasis Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Proteostasis Therapeutics' stock was trading at $1.16 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PTI shares have increased by 11.2% and is now trading at $1.29. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Proteostasis Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Proteostasis Therapeutics.

When is Proteostasis Therapeutics' next earnings date?

Proteostasis Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Proteostasis Therapeutics.

How were Proteostasis Therapeutics' earnings last quarter?

Proteostasis Therapeutics Inc (NASDAQ:PTI) announced its earnings results on Friday, May, 15th. The company reported ($0.19) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.26) by $0.07. View Proteostasis Therapeutics' earnings history.

What price target have analysts set for PTI?

5 brokerages have issued 1 year price objectives for Proteostasis Therapeutics' shares. Their forecasts range from $3.00 to $8.00. On average, they expect Proteostasis Therapeutics' share price to reach $5.20 in the next twelve months. This suggests a possible upside of 303.1% from the stock's current price. View analysts' price targets for Proteostasis Therapeutics.

Has Proteostasis Therapeutics been receiving favorable news coverage?

News articles about PTI stock have been trending extremely negative on Wednesday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Proteostasis Therapeutics earned a news sentiment score of -4.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the company's share price in the near future. View the latest news about Proteostasis Therapeutics.

Are investors shorting Proteostasis Therapeutics?

Proteostasis Therapeutics saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 3,080,000 shares, an increase of 10.0% from the May 31st total of 2,800,000 shares. Based on an average trading volume of 1,090,000 shares, the days-to-cover ratio is currently 2.8 days. Currently, 7.3% of the shares of the company are short sold. View Proteostasis Therapeutics' Current Options Chain.

Who are some of Proteostasis Therapeutics' key competitors?

What other stocks do shareholders of Proteostasis Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include BHP Group (BHP), Idera Pharmaceuticals (IDRA), Amarin (AMRN), Micron Technology (MU), Rite Aid (RAD), Clearside Biomedical (CLSD), Sorrento Therapeutics (SRNE), vTv Therapeutics (VTVT), Anavex Life Sciences (AVXL) and Syndax Pharmaceuticals (SNDX).

Who are Proteostasis Therapeutics' key executives?

Proteostasis Therapeutics' management team includes the following people:
  • Ms. Meenu Chhabra, Pres, CEO, Interim Principal Financial & Accounting Officer and Director (Age 48, Pay $844.78k)
  • Ms. Sheila Gilbride Wilson M.B.A., Chief Operating Officer (Age 62, Pay $521.96k)
  • Dr. Po-Shun Lee, Consultant (Age 51, Pay $545.85k)
  • Dr. Marija Zecevic, Chief Commercial Officer (Age 46, Pay $530.46k)
  • Dr. Benito Munoz, Chief Scientific Officer (Age 58)

When did Proteostasis Therapeutics IPO?

(PTI) raised $51 million in an initial public offering (IPO) on Thursday, February 11th 2016. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

What is Proteostasis Therapeutics' stock symbol?

Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."

How do I buy shares of Proteostasis Therapeutics?

Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Proteostasis Therapeutics' stock price today?

One share of PTI stock can currently be purchased for approximately $1.29.

How big of a company is Proteostasis Therapeutics?

Proteostasis Therapeutics has a market capitalization of $67.27 million and generates $5 million in revenue each year. The company earns $-59,130,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Proteostasis Therapeutics employs 44 workers across the globe.

What is Proteostasis Therapeutics' official website?

The official website for Proteostasis Therapeutics is www.proteostasis.com.

How can I contact Proteostasis Therapeutics?

Proteostasis Therapeutics' mailing address is 80 Guest Street Suite 500, Boston MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected]

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.